Silicon Laboratories Inc. Condensed Consolidated Balance Sheets (In thousands, except per share data) (Unaudited) | |||
| |||
| March 30,
|
| December 30,
|
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents | $ 191,489 |
| $ 227,504 |
Short-term investments | 141,201 |
| 211,720 |
Accounts receivable, net | 32,616 |
| 29,295 |
Inventories | 198,206 |
| 194,295 |
Prepaid expenses and other current assets | 82,608 |
| 75,117 |
Total current assets | 646,120 |
| 737,931 |
Property and equipment, net | 142,155 |
| 145,890 |
Goodwill | 376,389 |
| 376,389 |
Other intangible assets, net | 53,453 |
| 59,533 |
Other assets, net | 126,036 |
| 123,313 |
Total assets | $ 1,344,153 |
| $ 1,443,056 |
Liabilities and Stockholders' Equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable | $ 44,575 |
| $ 57,498 |
Revolving line of credit | — |
| 45,000 |
Deferred revenue and returns liability | 3,921 |
| 2,117 |
Other current liabilities | 62,863 |
| 58,955 |
Total current liabilities | 111,359 |
| 163,570 |
Other non-current liabilities | 67,233 |
| 70,804 |
Total liabilities | 178,592 |
| 234,374 |
Commitments and contingencies |
|
|
|
Stockholders' equity: |
|
|
|
Preferred stock – $0.0001 par value; 10,000 shares authorized; no shares issued | — |
| — |
Common stock – $0.0001 par value; 250,000 shares authorized; 31,924 and 31,897 shares issued and outstanding at March 30, 2024 and December 30, 2023, respectively | 3 |
| 3 |
Additional paid-in capital | 29,830 |
| 16,973 |
Retained earnings | 1,136,205 |
| 1,192,731 |
Accumulated other comprehensive loss | (477) |
| (1,025) |
Total stockholders' equity | 1,165,561 |
| 1,208,682 |
Total liabilities and stockholders' equity | $ 1,344,153 |
| $ 1,443,056 |